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Background: Indigenous and/or minority ethnic women are known to experience longer delays for treatment of
breast cancer, which has been shown to contribute to ethnic inequities in breast cancer mortality. We examined
factors associated with delay in adjuvant chemotherapy and radiotherapy for breast cancer, and its impact on the
mortality inequity between Indigenous Māori and European women in New Zealand.
Methods: All women with newly diagnosed invasive non-metastatic breast cancer diagnosed during 1999–2012,
who underwent adjuvant chemotherapy (n = 922) or radiation therapy (n = 996) as first adjuvant therapy after
surgery were identified from the Waikato breast cancer register. Factors associated with delay in adjuvant
chemotherapy (60-day threshold) and radiation therapy (90-day threshold) were analysed in univariate and
multivariate models. Association between delay in adjuvant therapy and breast cancer mortality were explored in
Cox regression models.
Results: Overall, 32.4% and 32.3% women experienced delays longer than thresholds for chemotherapy and
radiotherapy, respectively. Higher proportions of Māori compared with NZ European women experienced delays
longer than thresholds for adjuvant radiation therapy (39.8% vs. 30.6%, p = 0.045) and chemotherapy (37.3% vs.
30.5%, p = 0.103). Rural compared with urban residency, requiring a surgical re-excision and treatment in public
compared with private hospitals were associated with significantly longer delays (p < 0.05) for adjuvant therapy in
the multivariate model. Breast cancer mortality was significantly higher for women with a delay in initiating first
adjuvant therapy (hazard ratio [HR] =1.45, 95% confidence interval [CI] 1.05-2.01). Mortality risks were higher for
women with delays in chemotherapy (HR = 1.34, 95% CI 0.89-2.01) or radiation therapy (HR = 1.28, 95% CI 0.68-2.40),
although these were statistically non-significant.
Conclusions: Indigenous Māori women appeared to experience longer delays for adjuvant breast cancer treatment,
which may be contributing towards higher breast cancer mortality in Māori compared with NZ European women.
Measures to reduce delay in adjuvant therapy may reduce ethnic inequities and improve breast cancer outcomes
for all women with breast cancer in New Zealand.
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Ethnic disparities in receipt of breast cancer care are
well documented, and have been shown to contribute to-
wards worse breast cancer outcomes among Indigenous
and/or minority ethnic women [1,2]. Indigenous and/or
minority ethnic women are more likely to experience
longer delays in initiation of treatment for breast cancer
[3-5], which are known to increase risks of breast cancer
recurrence and mortality [6-9].
Indigenous Māori, who make up about 15% of New
Zealand population, carry a greater burden of breast
cancer due to a higher incidence and a lower survival
compared with NZ European women [10]. Advanced
cancer stage at diagnosis in Māori women is known to
have the greatest impact on breast cancer survival dis-
parity between these two groups. Still, stage adjusted
breast cancer mortality is about 30% higher for Māori
women indicating a significant contribution from factors
other than stage at diagnosis, including possible differ-
ences in treatment quality and delays in treatment [10].
A substantial reduction in breast cancer mortality has
been observed in developed countries over the last two
decades, which has been attributed to earlier diagnosis
with widespread use of screening mammography and ad-
vances in breast cancer treatment [11]. Timeliness of insti-
tuting treatment is crucial in order to obtain the maximum
potential benefit from these new and advanced treatments.
Two recent meta-analyses have shown a 6% and 15% in-
crease in relative mortality rate with each 4-week delay in
initiating adjuvant chemotherapy [12,13]. Although timeline
thresholds given in treatment guidelines are sometimes ar-
bitrary and controversial, longer delays for surgery, chemo-
therapy and radiation therapy have all been proven to be
associated with poorer breast cancer outcomes including
higher risks of recurrence and mortality [6,8,9,12,13].
In New Zealand, longer delays experienced by Māori
in the receipt of cancer care have been reported for surgi-
cal treatment of breast and lung cancer [14,15] and for re-
ceipt of adjuvant chemotherapy for bowel cancer [16]. To
date, no data are available on delays in adjuvant therapy
experienced by New Zealand women with breast cancer
or ethnic differences in the receipt of such treatment.
We conducted this study to identify ethnic differences
in delay in initiating adjuvant chemotherapy or radiation
therapy following surgical treatment for invasive breast
cancer. We also explored time trends in delays and impact
of delay on breast cancer outcomes in this cohort of
women with breast cancer.
Methods
Study population
Data for this study were extracted from the Waikato
breast cancer register (WBCR), a population based, pro-
spective, comprehensive database of newly diagnosedbreast cancers in the Waikato, New Zealand since 1999.
The WBCR includes over 98% of all diagnosed cancers
in the region and validity of its data has been reported
previously [17]. All newly diagnosed invasive female breast
cancers during the period from 01/01/1999 through
31/12/2012, were identified from the WBCR (n = 2848).
Of this, women with metastatic cancer (stage IV disease)
at diagnosis (n = 166), women who did not undergo
primary surgery (n = 114) and women who received
neo-adjuvant therapy (n = 87), were excluded.
Healthcare system in New Zealand and breast cancer
services in the Waikato
New Zealand has a well-resourced publicly funded na-
tional health system that provides specialist and hospital
care to all citizens without patient charges. Parallel to
the public system, there are a variety of private hospital
facilities available, which are mostly funded through in-
surance schemes. A national breast cancer screening
programme, BreastScreen Aotearoa (BSA) provides free
biannual breast cancer screening for all women aged
45–69 years. The Waikato region with a population of
365,000 is the fourth largest of twenty District Health
Boards in New Zealand. It has a major urban centre, a
significant rural population and a Māori population of
almost 80,000. Public sector breast cancer services in the
Waikato are provided through specialist services at the
district tertiary hospital in Hamilton. In addition, surgical
treatment is also provided through several well-equipped
private hospitals. Radiation therapy services for the
Waikato region are provided exclusively through the ra-
diation facility at the tertiary hospital in Hamilton, while
chemotherapy facilities are provided through a satellite
site in addition to the tertiary hospital in Hamilton.
Data
Patient ethnicity was obtained from the WBCR, which
records self-assigned ethnicity as declared by each patient
during the WBCR consent process. Ethnicity was grouped
into four categories; Māori, Pacific (including Samoan,
Cook Island Māori, Tongan, Niuean, Tokelauan, Fijian and
other Pacific Islands), NZ European, and ‘Other’. Cancer
staging was performed according to TNM (Tumour,
Lymph node and Metastasis) staging system [18].
Socioeconomic status of each woman was categorized
according to the New Zealand Deprivation Index 2006
(NZDep06) [19]. NZDep06 measures socioeconomic sta-
tus based on area of residence and assigns a deprivation
score on a scale from 1 to 10 (1-least deprived 10% of
areas, 10-most deprived 10% of areas in New Zealand)
based on nine parameters measured during the popula-
tion census in 2006. Distance from a woman’s residence
to treatment facility where surgery was carried out was
calculated based on New Zealand Statistics [20] and was
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50–100 and >100 km.
A comorbidity score for each woman was calculated
using Charlson Comorbidity Index [21], based on existing
comorbidities at the time of diagnosis of breast cancer.
Comorbidity score was categorized in to 0 or ≥1.
Delay in adjuvant therapy
To assess time gap from surgery to initiation of first ad-
juvant therapy (i.e. chemotherapy or radiation therapy),
all women with non-metastatic invasive breast cancer
undergoing surgery as primary breast cancer treatment
modality were identified (n=2481). Chemotherapy was
considered as the first adjuvant therapy for all eligible
women undergoing adjuvant chemotherapy (n=922, 37.2%)
and radiation therapy was considered as the first adjuvant
therapy for women undergoing radiation therapy without
prior adjuvant chemotherapy (n=996, 40.1%). The time
gap to adjuvant chemotherapy and radiation therapy was
defined as number of days from the most definitive oper-
ation for the breast cancer to the first administration of
chemotherapy or radiation therapy [5]. The definitive sur-
gical procedure at the primary site captured the most in-
vasive surgical procedure at the primary site and included
excisional biopsy, wide local excision and mastectomy.
Women who had delays of more than 365 days for either
chemotherapy or radiation therapy were excluded.
A threshold of 60 days was used as the acceptable
threshold delay for initiating chemotherapy, based on evi-
dence from three recently published papers. These include
two meta-analyses which have demonstrated 6% and 15%
worse overall and disease free relative mortality rates for
each 4-week delay in initiating chemotherapy [12,13]. A
third study from the USA, which included more than
6000 women found significantly worse disease free sur-
vival for women with stage II-III or triple negative or
HER-2 positive cancers, who experienced delays longer
than 60 days [9]. As some previous studies have used a
90-day threshold delay for chemotherapy [7,22-24], we
performed additional analyses with a 90-day threshold for
chemotherapy. For radiation therapy, a 90-day threshold
was used, which has conventionally been used in the as-
sessment of radiation therapy delay [8].
Data analysis
Data were analysed using SPSS (version 22). Continuous
variables were summarized as mean/median with standard
deviation (SD). Independent samples median test was used
to test differences in continuous variables. Chi squared
tests (χ2) for trend was used to test differences in delay
among groups including age, ethnicity, stage, mode of
diagnosis (screen detected or symptomatic) and year of
diagnosis. Multivariable logistic regression analyses were
performed to estimate independent association betweenabove factors and delays in initiating adjuvant therapy.
Separate Cox regression models were used to identify
the association between breast cancer specific mortality
and delay (overall, chemotherapy and radiation therapy)
adjusting for covariates.
Ethical approval for this study was obtained from the
New Zealand Northern ‘A’ Ethics Committee (Ref. No.
12/NTA/42).
Results
This study included a total of 1918 women of whom 922
(711 NZ European and 153 Māori) received chemotherapy
and 996 (853 NZ European and 113 Māori) received radi-
ation therapy as first adjuvant therapy. The median time
gap for initiating adjuvant chemotherapy was 49 days
(mean 52.6, SD 21.3) and for adjuvant radiation therapy
was 76 days (mean 81.4, SD 32.5). Māori women experi-
enced significantly longer median delays compared with
NZ European women for both adjuvant chemotherapy
(median delay 54 vs. 49 days, p = 0.017) and radiation
therapy (median delay 83 vs. 75 days, p = 0.046). Over-
all, 318 (31.9%) women experienced a delay longer than
90 days to receive radiation therapy and the number of
women who did not receive chemotherapy within 60-
day threshold was 301 (32.4%). A total of 619 (32.3%)
women experienced a delay in receiving first adjuvant
therapy. Five percent (n = 46) women experienced a
delay longer than 90 days for chemotherapy. A signifi-
cantly higher proportion of Māori women experienced a
delay longer than 90 days compared with NZ European
women (8.7% vs. 4.2%, p = 0.025).
Univariate analysis of factors associated with delay in
receiving first adjuvant therapy, chemotherapy and radi-
ation therapy are shown in Table 1 and the multivariable
logistic regression in Table 2. Māori or Pacific ethnicity
compared with NZ European ethnicity, earlier year of
diagnosis, requiring a re-excision following primary sur-
gery, longer distance from the tertiary care hospital and
receiving surgical treatment from a public versus private
hospital were associated with significantly longer delays
(p < 0.05) for first adjuvant therapy in both unadjusted
and adjusted models. For chemotherapy, a significant in-
verse association (p = 0.048) was observed between stage
and proportion with delays longer than 60 days with the
smallest proportion observed for stage III disease. Delays
longer than threshold limits for chemotherapy and ra-
diation therapy were significantly associated with re-
excisions after primary surgery and treatment in public
hospital in both univariate and multivariate models.
Distance from treatment facility was significantly associ-
ated with delay in radiation therapy (p = 0.021), but not
for delay in chemotherapy (p = 0.540). Delay for radiation
therapy has significantly reduced over time (p < 0.001),
while delays for chemotherapy have increased during
Table 1 Factors associated with delay in adjuvant therapy
Characteristic Total (N = 1918) Delay in first adjuvant
therapya




n (%) n (%) p n (%) p n (%) p
Ethnicity
NZ European 1564 (81.5) 478 (30.6) 261 (30.6) 217 (30.5)
Māori 266 (13.9) 101 (38.0) 0.022 45 (39.8) 0.045 57 (37.3) 0.103
Pacific 38 (2.0) 19 (50.0) 0.013 6 (54.5) 0.101 13 (48.1) 0.057
Other 50 (2.6) 21 (42.0) 0.112 7 (35.0) 0.676 14 (46.7) 0.065
Age (years) 0.846 0.704 0.091
<40 117 (6.1) 38 (32.5) 9 (40.9) 29 (30.5)
40-49 433 (22.6) 130 (30.0) 43 (32.8) 87 (28.8)
50-59 583 (30.4) 193 (33.1) 89 (34.2) 104 (32.2)
60-69 494 (25.8) 165 (33.4) 94 (29.2) 71 (41.3)
70-79 212 (11.1) 70 (33.0) 60 (33.0) 10 (33.3)
80+ 79 (4.1) 23 (29.1) 23 (29.1) 0
Stage at diagnosis <0.001 <0.001 0.048
I 800 (41.7) 228 (28.5) 176 (27.0) 52 (35.4)
II 772 (40.3) 291 (37.7) 112 (43.1) 179 (35.0)
III 346 (18.0) 100 (28.9) 30 (36.1) 70 (26.6)
Year of diagnosis <0.001 <0.001 <0.001
1999-2002 393 (20.5) 166 (42.2) 105 (62.5) 61 (27.1)
2003-2006 579 (30.2) 181 (31.3) 107 (35.9) 74 (26.3)
2007-2009 452 (23.6) 146 (32.3) 50 (20.0) 96 (47.5)
2010-2012 494 (25.8) 126 (25.5) 56 (20.0) 70 (32.7)
Screening status 0.162 0.005 0.247
Non-screen 1110 (57.9) 372 (33.5) 171 (36.3) 201 (31.5)
Screen detected 808 (42.1) 247 (30.6) 147(28.0) 100 (35.3)
Deprivation 0.257 0.795 0.147
Dep 1-2 213 (11.1) 55 (25.8) 29 (28.7) 26 (23.2)
Dep 3-4 206 (10.7) 66 (32.0) 36 (34.3) 30 (29.7)
Dep 5-6 487 (25.4) 161 (33.1) 75 (29.8) 86 (36.6)
Dep 7-8 532 (27.7) 174 (32.7) 98 (32.7) 76 (32.8)
Dep 9-10 480 (25.0) 163 (34.0) 80 (33.6) 83 (34.3)
Primary surgery 0.913 0.014 0.058
BCS 1318 (68.7) 425 (32.2) 260 (30.4) 165 (35.6)
Mastectomy 600 (31.3) 194 (32.3) 58 (40.8) 136 (29.7)
Re-excision <0.001 <0.001 0.002
No 1659 (86.5) 491 (29.6) 250 (28.6) 241 (30.7)
Yes 259 (13.5) 128 (49.4) 68 (55.3) 60(44.1)
Distance from hospital 0.019 0.021 0.540
<10 km 630 (32.8) 192 (30.5) 94 (28.1) 98 (33.1)
10-50 km 740 (38.6) 221 (29.9) 107 (29.2) 114 (30.5)
50-100 km 462 (24.1) 169 (36.6) 100 (38.9) 69 (33.7)
>100 km 86 (4.5) 37 (43.0) 17 (43.6) 20 (42.6)
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Table 1 Factors associated with delay in adjuvant therapy (Continued)
Surgical facility type <0.001 0.009 0.001
Private 632 (33.0) 163 (25.8) 73 (25.8) 90 (25.8)
Public 1286 (67.0) 456 (35.5) 245 (34.4) 211 (36.8)
Charlson score 0.175 0.434 0.520
0 1677 (87.4) 534 (31.8) 265 (31.7) 269 (32.0)
1+ 241 (12.6) 85 (35.3) 53 (33.3) 32 (39.0)
(Univariate analysis for factors associated with delay in first adjuvant therapy a, delay in radiation therapy longer than 90 days and delay in chemotherapy longer
than 60 days for women with newly diagnosed invasive breast cancer in the Waikato, New Zealand during 1999-2012.
adelay in radiation therapy longer than 90 days or delay in chemotherapy longer than 60 days.
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2012.
Adjusted multivariable logistic regression model iden-
tified year of diagnosis, re-excision and surgical treat-
ment facility type to be independently associated with
delay in first adjuvant therapy as well as for delay in
chemotherapy and radiation therapy (Table 2). Overall,
Māori, Pacific and Other ethnicity were associated with
higher likelihoods of delay for chemotherapy, radiation
therapy and for first adjuvant therapy, although this was
statistically significant only for delay in radiotherapy for
Māori and delay in first adjuvant therapy for Pacific
women in the multivariable model. Sensitivity analysis
with 90-day chemotherapy delay threshold yielded simi-
lar results in the multivariable regression model (data
not shown) with year of diagnosis (OR = 1.37, p < 0.001),
re-excision (OR = 3.96, p = 0.001) and public hospital
care (OR = 4.89, p = 0.001) showing significant associa-
tions. Māori women had a non-significantly higher risk
for a chemotherapy delay longer than 90 days (OR =
1.41, p = 0.291) compared with NZ European women in
this model.
Time trends in 60-day chemotherapy and 90-day radi-
ation therapy delay by ethnicity is shown in Figure 1.Table 2 Multivariable model for factors associated with delay
Delay in first adjuvant therapya Delay in
OR 95% CI p OR
Ethnicity
NZ European Ref. Ref
Māori 1.32 0.98-1.77 0.069 1.87
Pacific 2.05 1.03-4.08 0.041 2.47
Other 1.71 0.94-3.11 0.082 1.32
Year of diagnosisb 0.79 0.72-0.87 <0.001 0.49
Re-excision 2.47 1.85-3.28 <0.001 3.55
Surgical facility typec 1.53 1.22-1.93 <0.001 1.59
Distance from hospitald 1.10 1.02-1.18 0.024 1.23
(Multivariable logistic regression model for factors associated with delay in first adju
chemotherapy longer than 60 days adjusting for age, tumour stage, socioeconomic
aDelay in radiation therapy longer than 90 days or delay in chemotherapy longer than
cReference category private surgical facility, dReference category <10 km.Higher proportions of Māori women have consistently
experienced longer delays for radiation therapy compared
with NZ European women over the study period which
were significant during 2003–2006 and 2007–2009 periods
(p = 0.010 and p = 0.012, respectively). The reduction in
radiation therapy delay has been greater for NZ European
than for Māori over 1999–2009, which has resulted in a
widening of disparity in delay between Māori and NZ
European, although this gap seems to have narrowed over
the last three year period of the study. Higher proportions
of Māori have experienced delays longer than 60 days
for chemotherapy over 1999–2009 period, but since
has declined below the rate for NZ European women
over 2010–2012. For delays in chemotherapy longer
than 90 days (Figure 1), the highest proportion was seen
during 2007–2009 period (overall 10.9%, NZ European
9.7%, Māori 15.8%) and since has declined to 5.2% (NZ
European 4.6%, Māori 6.8%) during 2010–2012.
A survival analysis using a multivariable Cox regression
analysis adjusting for covariates showed a significantly
higher breast cancer specific mortality risk (HR = 1.45,
p = 0.024) among women who experienced delays in
first adjuvant therapy (Table 3). A sensitivity analysis
with a 90-day delay threshold for chemotherapy yieldedin adjuvant therapy
radiation therapy >90 days Delay in chemotherapy >60 days
95% CI p OR 95% CI p
Ref
1.17-3.02 0.010 1.17 0.78-1.74 0.452
0.54-11.2 0.242 1.87 0.82-4.26 0.136
0.46-4.05 0.564 2.03 0.93-4.44 0.076
0.42-0.56 <0.001 1.17 1.03-1.34 0.017
2.32-5.44 <0.001 1.81 1.19-2.73 0.005
1.12-2.26 0.010 1.58 1.15-2.16 0.005
1.09-1.39 0.001 1.03 0.92-1.15 0.654
vant therapy, delay in radiation therapy longer than 90 days and delay in
deprivation and comorbidity score).
60 days, bYear categories as in Table 1 and reference category year 1999–2002,
Figure 1 Time trends in delay in adjuvant therapy (time trends in delay in adjuvant chemotherapy longer than 60 and 90 days (Panel
A) and adjuvant radiation therapy longer than 90 days (Panel B) for invasive breast cancer in the Waikato, New Zealand 1999–2012).
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women who experienced a delay for first adjuvant therapy
(HR = 1.29, 0.81-2.05, p = 0.288), although this difference
was no longer statistically significant. Delay in chemo-
therapy (HR = 1.34, p = 0.157) and radiation therapy
(HR = 1.28, p = 0.449) were also tended to be associated
with higher hazards of breast cancer mortality although
these did not reach statistical significance.
Discussion
From this study we found that among women with non-
metastatic invasive breast cancer in the Waikato, New
Zealand, almost a third (32.3%) experienced a delay in
initiating radiation therapy or chemotherapy as first ad-
juvant therapy following primary surgical treatment.
Furthermore, Māori and Pacific compared with NZ
European, rural compared with urban dwelling women
and women who received surgical treatment in public
compared with private hospitals had significantly higher
likelihoods of experiencing delays longer than thresholdsTable 3 Proportional hazard models for breast cancer
specific mortality
HRab 95% CI p
Delay in first adjuvant therapy 1.45 1.05-2.01 0.024
Delay in radiotherapy >90 days 1.28 0.68-2.40 0.449
Delay in chemotherapy >60 days 1.34 0.89-2.01 0.157
(Cox proportional models for breast cancer specific mortality by delay in first
adjuvant therapy, radiation therapy and chemotherapy).
aPerformed in three separate Cox regression models, bFor stage I-III invasive
breast cancer adjusted for age, ethnicity, stage of disease (i.e. tumour size and
number of positive lymph nodes), tumour grade, oestrogen receptor status,
lympho-vascular invasion, year of diagnosis, comorbidity score and receipt of
adjuvant therapy.for adjuvant therapy. Increasing socioeconomic deprivation
tended to be non-significantly associated with longer delays
in adjuvant therapy while no association was observed
between delay and patient age. Although delay in radi-
ation therapy seems to have improved over time, sub-
stantial proportions of women continue to experience
clinically significant delays for both chemotherapy and
radiation therapy.
Delays in adjuvant therapy for breast cancer experienced
by disadvantaged populations including minority and Indi-
genous ethnic groups are well documented [1,2]. From a
study based on over 100,000 women from the US National
Cancer Database, Fedewa and colleagues reported that
Black African women were 30% and 50% more likely to
experience delays longer than 60 and 90 days respectively,
for initiation of adjuvant chemotherapy compared with
White European women [5]. We observed a similar pat-
tern where greater proportions of Māori women experi-
enced longer delays for chemotherapy (23% higher for
60-day and 100% higher for 90-day delay) compared
with NZ European women. However, from 2007–2009,
there were no significant inequities between Māori and
NZ European women and, in 2010–2012 Māori women
were less likely to experience a delay in accessing
chemotherapy. Timeliness in initiating treatment for
breast cancer is of greater importance for women with
more advanced or more aggressive cancers (i.e. stage II
or III, hormone receptor negative, HER-2 positive) [9,25].
Māori women are more likely to be diagnosed with more
advanced disease and are more likely to have hormone re-
ceptor negative and HER-2 positive breast cancers [10,26],
and hence longer delays in adjuvant therapy, as demon-
strated in this study are likely to have a greater impact on
Seneviratne et al. BMC Cancer 2014, 14:839 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/839breast cancer survival in Māori women. However, women
with more advanced cancers seem to have had shorter de-
lays, possibly due to prioritized care for these higher risk
women and, hence likely to have had a minimal differen-
tial impact on higher mortality in Māori compared with
NZ European women.
Delays in cancer adjuvant therapy are associated with
factors including lack of access to healthcare, difficulties
with navigating the health system, geographic distance
to treatment facility, availability of transport and ability
to take time-off work to attend adjuvant therapy [1,27,28].
Further, women of some ethnic minority populations in-
cluding Black Africans in the USA have been shown to
be less willing to undergo adjuvant treatments because
of greater fear of side-effects and lack of knowledge on
potential benefits [29,30]. Longer delays for adjuvant
therapy observed among Māori compared with NZ
European women in this study were likely due to a com-
bination of these factors as Māori are more likely to be
socioeconomically deprived and live in rural areas with
less access to transport compared with NZ Europeans
[31]. These differences were observed despite temporary
accommodation and/or free transport been provided by
the Waikato District Health Board for women requiring
these facilities to attend adjuvant chemotherapy and ra-
diation therapy. Furthermore, the higher risk of Māori
compared with NZ European women for longer delays
persisted even after adjusting for deprivation and resi-
dence which probably was due to the impact of unmeas-
ured or under-measured confounders in the present
study. For instance, Māori women are more likely to
have lower levels of education, lower health literacy and
are less likely to have a health insurance policy com-
pared with NZ European women [31], factors which are
known to be associated with longer delays in cancer
treatment [5]. These factors were not included in our
analyses due to unavailability of these data from the
WBCR. We also observed that significantly smaller pro-
portions of women who received surgical treatment in
the private sector had experienced delays beyond the
threshold limits for both chemotherapy and radiation
therapy compared with women treated in the public
sector. Ability to afford treatment from private sector
has a strong correlation with higher socioeconomic sta-
tus and/or having a health insurance policy. Hence, this
observation supports, though indirectly, affluent socio-
economic background and health insurance as factors
influencing shorter delays in the receipt of adjuvant
therapy. This disparity is observed, despite more than
95% women included in the present study receiving
their adjuvant chemotherapy and radiation therapy free
of charge from the public sector.
Rural residency is known to influence delay as well as a
woman’s decision to undergo adjuvant radiation therapyfor breast cancer [32]. Radiation therapy requires women
to attend a radiation facility five days a week over a period
ranging from three to six consecutive weeks and due to
this many rural women prefer mastectomy over BCS
[14,32]. This is of greater importance for the study women
as the Waikato district health board covers an area of over
20,000 square kilometres and yet has provided radiation
therapy services through a single central facility. In com-
parison, chemotherapy in most instances requires only
once in three weeks and/or once a week visits to a chemo-
therapy facility and is less likely to be influenced by rural
residence. Consistent with this, no significant differences
in delays for chemotherapy were observed between urban
and rural women in the present study.
Several effective strategies for minimizing delays in ad-
juvant therapy and reducing inequities in delay between
socioeconomic and ethnic groups are reported in litera-
ture. These include improving access through increasing
supply or efficient usage of existing cancer resources
through coordinated cancer care, decentralization of can-
cer services and through improving patient health literacy
[33-36]. As we have observed, almost a third of women
have experienced delays in adjuvant therapy beyond the
threshold limits and it appears that overloading of oncol-
ogy services was a likely factor. The greatest proportion of
women experiencing delays longer than three months for
radiation therapy was seen during 1999–2002 which was a
time when a severe nationwide shortage of radiation ther-
apy services was experienced in New Zealand [37]. Since
then the supply of radiation facilities has increased result-
ing in a gradual reduction in proportion of women experi-
encing delays longer than three months. However, the
increase in supply of radiation therapy facilities has been
inadequate or lagging behind to keep up with the increase
in number of patients requiring radiation therapy. As a re-
sult, even in 2010–2012, about 20% women were observed
to have experienced delays longer than three months for
radiation therapy. Delays in chemotherapy appeared to
have worsened during 1999–2009 followed by an improve-
ment in the last time period. These different patterns of
delay in chemotherapy and radiation therapy may reflect
issues at national level as well as local issues of service
capacity compared with demand.
Increasing the supply of oncology services alone are
unlikely to eliminate inequities in delay, as disadvantaged
women (i.e. ethnic minority, socioeconomically deprived,
rural, etc.) will still be more likely to be subjected to longer
delays. Improved patient navigation through cancer care
coordinators (CCC) has been shown to help reduce delays,
especially for women who are at-risk for longer delays
which include women of minority ethnicity and low socio-
economic groups [38]. The Waikato District Health Board
has two full-time CCC’s providing support for women
with breast cancer since 2009. It is likely that CCCs have
Seneviratne et al. BMC Cancer 2014, 14:839 Page 8 of 9
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duction in delay overall and reduction in inequities be-
tween Māori and NZ European women observed
during 2010–2012. The Ministry of Health has also
identified CCC’s as a key strategy to increase quality
and reduce inequalities in cancer care, and since 2012
has provided funding for all District Health Boards to
employ CCC’s for management of common cancers in
New Zealand [39].
This study did not examine the type, duration, dose or
rates of completion of adjuvant chemotherapy or radiation
therapy which are also known to impact on the efficacy of
these adjuvant therapies [40,41]. Further, although we have
observed several associations with longer delays, we were
unable to identify causes for these delays i.e. whether
delays were due to longer wait time for appointments or
due to patients not attending appointments, additional
investigations required due to patient comorbidity, etc.
Another limitation of this study was the inclusion of
only small numbers of Pacific and Other women. Al-
though we have observed longer delays among Pacific
women small sample size prevented further analyses.
Further, we have used an area based deprivation system
as a proxy measure for individual socioeconomic
deprivation. Although the NZDep2006 has been vali-
dated as a proxy measure for individual derivation [42],
it inherently has a limited ability to predict individual
deprivation. Lack of a significant correlation between
deprivation score and delay in adjuvant therapy as ob-
served in this study could have been influenced by this
lack of precision. In addition, although the WBCR data
are highly complete [17], minor errors in misclassifica-
tions or data entry are inevitable. A stringent quality
control process including a regular audit of the database
is expected to have minimized, but not eliminated such
errors.Conclusions
In conclusion, we have observed significantly longer
delays experienced by Indigenous Māori women, rural
women and women receiving surgical care in the public
sector. Although delays in adjuvant therapy appear to
have improved over the study period, it is concerning
to note the substantial proportion of women continu-
ing to experience clinically significant delays for adju-
vant breast cancer therapy. Reducing delays through
improvements in availability, efficiency and access to
oncology services will not only minimize ethnic inequi-
ties in delay but may improve outcomes for all women
with breast cancer in New Zealand.Competing interests
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